Valuation: Penumbra, Inc.

Capitalization 13.36B 11.29B 10.31B 9.87B 18.24B 1,211B 18.91B 120B 47.64B 584B 50.09B 49.06B 2,052B P/E ratio 2025 *
79.1x
P/E ratio 2026 * 67.3x
Enterprise value 12.93B 10.93B 9.98B 9.56B 17.66B 1,172B 18.3B 116B 46.12B 565B 48.49B 47.49B 1,986B EV / Sales 2025 *
9.34x
EV / Sales 2026 * 8.06x
Free-Float
96.13%
Yield 2025 *
-
Yield 2026 * -
1 day+0.12%
1 week+0.88%
Current month-4.73%
1 month-4.00%
3 months+22.70%
6 months+33.63%
Current year+9.75%
1 week 338.05
Extreme 338.05
341.72
1 month 337.63
Extreme 337.63
362.41
Current year 290
Extreme 290
362.41
1 year 221.26
Extreme 221.26
362.41
3 years 148
Extreme 148
362.41
5 years 114.86
Extreme 114.865
362.41
10 years 41.35
Extreme 41.349
362.41
Manager TitleAgeSince
Chief Executive Officer 64 20/06/2004
President 42 31/08/2025
Director of Finance/CFO 54 01/12/2019
Director TitleAgeSince
Chairman 64 31/12/2014
Chairman 64 31/12/2004
Director/Board Member 59 31/03/2015
Change 5d. change 1-year change 3-years change Capi.($)
+0.12%+0.88%+25.85%+32.16% 13.36B
+0.32%+29.80%-2.82%+8.94% 9.12B
+0.70%+0.48%-5.33%-13.56% 6.02B
-1.81%-3.73%+2.29%+26.25% 5.48B
-0.49%+13.33%+10.43%+24.58% 5.13B
-1.79%-3.64%-8.08%+44.37% 4.75B
-1.64%-3.39%+7.54%-57.37% 1.66B
+0.11%+0.87%+18.82%+22.91% 1.46B
+0.28%+12.78%+6.87%-9.67% 1.35B
+1.21%+7.29%-48.91%-86.05% 1.25B
Average -0.30%+1.78%+0.67%-0.74% 4.96B
Weighted average by Cap. -0.26%+0.06%+6.12%+14.68%

Financials

2025 *2026 *
Net sales 1.38B 1.17B 1.07B 1.02B 1.89B 125B 1.96B 12.47B 4.94B 60.53B 5.19B 5.09B 213B 1.58B 1.34B 1.22B 1.17B 2.16B 143B 2.24B 14.25B 5.64B 69.19B 5.93B 5.81B 243B
Net income 169M 143M 131M 125M 231M 15.34B 240M 1.52B 604M 7.4B 635M 622M 26B 200M 169M 154M 148M 273M 18.12B 283M 1.8B 713M 8.74B 750M 734M 30.7B
Net Debt -427M -361M -330M -315M -583M -38.68B -604M -3.84B -1.52B -18.66B -1.6B -1.57B -65.55B -607M -513M -469M -449M -829M -55.05B -860M -5.47B -2.17B -26.55B -2.28B -2.23B -93.28B
Logo Penumbra, Inc.
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Employees
4,500
Date Price Change Volume
18/02/26 341.09 $ +0.02% 39,584
17/02/26 341.03 $ +0.51% 446,315
13/02/26 339.30 $ +0.17% 551,721
12/02/26 338.72 $ +0.14% 778,105
11/02/26 338.26 $ -0.21% 701,461
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
18
Last Close Price
341.03USD
Average target price
348.53USD
Spread / Average Target
+2.20%

Quarterly revenue - Rate of surprise